A critical aspect of lead identification in drug discovery is
the bioactivity screening assay, by which compounds that
most effectively inhibit or activate the enzyme target are
identified. The screening assay should be representative
of the in vivo setting so that the results can be interpreted,
with sufficient confidence, from the viewpoint of clinical
efficacy. The requirements for a good screening assay
include high target specificity and sensitivity, reproducibility
and robustness. In addition, the choice of a screening
assay in high-throughput format calls for ease ofincreasing
levels of interest in the pharmaceutical industry as a productive and cost-effective
technology in the search for novel lead compounds. Although the principles involvedthe computational analysis of chemical databases to identify compounds appropriate
for a given biological receptor-have been pursued for several years in molecular
modeling groups, the availability of inexpensive high-performance computing
platforms has transformed the process so that increasingly complex and more
accurate analyses can be performed on very detailed and relevant basis for
prioritizing compounds for biological screening. Virtual screening offers a practical
route to discovering new reagents and lead for pharmaceutical research.
A critical aspect of lead identification in drug discovery is
the bioactivity screening assay, by which compounds that
most effectively inhibit or activate the enzyme target are
identified. The screening assay should be representative
of the in vivo setting so that the results can be interpreted,
with sufficient confidence, from the viewpoint of clinical
efficacy. The requirements for a good screening assay
include high target specificity and sensitivity, reproducibility
and robustness. In addition, the choice of a screening
assay in high-throughput format calls for ease ofincreasing
levels of interest in the pharmaceutical industry as a productive and cost-effective
technology in the search for novel lead compounds. Although the principles involvedthe computational analysis of chemical databases to identify compounds appropriate
for a given biological receptor-have been pursued for several years in molecular
modeling groups, the availability of inexpensive high-performance computing
platforms has transformed the process so that increasingly complex and more
accurate analyses can be performed on very detailed and relevant basis for
prioritizing compounds for biological screening. Virtual screening offers a practical
route to discovering new reagents and lead for pharmaceutical research.
การแปล กรุณารอสักครู่..